Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/medicine-technology-1/nuvasive-appoints-new-chief-financial-officer-and-announces-additional-management-updates-6053-5/;msg18067;topicseen) was not found.

Search medicine technology 1 nuvasive appoints new chief financial officer and announces additional management updates 6053 5 ;msg18067;topicseen at Google

Search medicine technology 1 nuvasive appoints new chief financial officer and announces additional management updates 6053 5 ;msg18067;topicseen at Yahoo

Search medicine technology 1 nuvasive appoints new chief financial officer and announces additional management updates 6053 5 ;msg18067;topicseen at Msn

Google
 
(Date:12/2/2009)...wswire/ -- DigitalPersona, Inc., a leader in finge...y announced an agreement with IBM to deploy a new ...technology on IBM SurePOS 500 retail systems. The ...s point-of-sale applications to more easily and qu... can be linked to the individuals who perform them...
(Date:12/2/2009)...a and another from Yale University have shown that...f Acanthodactylus beershebensis , a lizard specie...g to the study, these reptiles move less and catch...pressure from predators. , Many theoretical mode...had been very few experimental trials and none in ...
(Date:12/1/2009)...unce the publication of results from its Phase II ...rability of its novel, intranasal drug/device prod...sitis with nasal polyps in Rhinology , the offici...logic Societies. , Chronic rhinosinusitis with ...cantly reduce a patient,s quality of life, causing...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Lizards change their diet to avoid predators 2New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Transdel Pharmaceuticals Enters Into License Agreement with JH Direct LLC for Cosmeceutical Product 48420 1Transdel Pharmaceuticals Enters Into License Agreement with JH Direct LLC for Cosmeceutical Product 48420 2Transdel Pharmaceuticals Enters Into License Agreement with JH Direct LLC for Cosmeceutical Product 48420 3Transdel Pharmaceuticals Enters Into License Agreement with JH Direct LLC for Cosmeceutical Product 48420 4Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 1Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 2Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 3Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 4Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 5Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 6Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 7Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 8Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 9AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5
(Date:12/2/2009)...Constraint-induced movement therapy (CIMT) is a po...ren with hemiplegic cerebral palsy, but more resea...w published in the November issue of Physical The...n Physical Therapy Association (APTA). The review,...ematic reviews, concluded that further research sh...
(Date:12/2/2009)... Revolutionary new cell phones that direct ...l be available in early 2010 from Aerius Internati...mber 2, 2009 -- Revolutionary new cell phones that...sers will be available in early 2010 from Aerius I...red with a Green Technology Award in wireless comm...
(Date:12/2/2009)... A team of Kendall Hunt authors earned the ...d at the recent National Association for Gifted Ch...ember 5-7, 2009. , Dubuqu...l Hunt authors earned the 2009 Gifted Child Quarte... Association for Gifted Children’s annual co...
(Date:12/2/2009)...HINGTON, Dec. 2 Pro-abo..., December 2 in their campaign against the U.S. Ho... Americans United for Life President and CEO Charm...the abortion lobby,s effort to expand taxpayer fun...h health care, the feminist groups and the abortio...
(Date:12/2/2009)...S ANGELES, Dec. 2 At a ...Tourism ministerial delegates came together to out...equired to give it the necessary thrust. Organized...edicaltourismassociation.com , the high-powered co...iscussed the opportunities and requests for assist...
Breaking Medicine News(10 mins):Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3
...olabeled Ligands\n\nReceptor-related research has ... new radiolabeled ligands selected to keep pace wi...e of products and services for receptor research a...-art radioligands. If you do not find exactly what...
Taq DNA Polymerase, 500 U (2 x 250 U) without dNTP from Bioneer, Inc.
iTaq DNA Polymerase, 5,000 U from Bio-Rad
Rabbit Anti-hnRNP-U Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products:
Alloclassic Hip
Perfecta RS Stems
S-ROM Femoral Stems - XX-Long Length Stems 36mm Neck with 21mm Calcar Replacement + Lat Neck
S-ROM Femoral Stems - Long Length Stems Standard 36mm Neck
Medicine Products:
(Date:12/2/2009)...., Dec. 2 TechConnect World, an ev...velopment and product integration in cleantech, na...1th deadline for technology abstracts and business...nnect World, in association with the Nano Science ...hnology and Sustainable Industries Organization (C...
(Date:12/2/2009)..., Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutic... ), a leading pharmaceutical company,specializing ...f branded,generic and proprietary pharmaceuticals ...ve been included in China,s National Drug Reimburs...inistry of Human Resources and Social,Security on ...
(Date:12/2/2009)...2 According to the National Instit...ns diagnosed with diabetes already have some stage...amage to the retina caused by leaky blood vessels,...etes and is one of the most feared diabetic compli...s who,ve had diabetes for 10 years or more will ex...
(Date:12/1/2009)...1 Reportlinker.com announces that ...atalogue: ,, Industrial Enzymes - A Global Mar...64431/Industrial-Enzymes---A-Global-Market-Report....oly with few strong players and a host of small su...ompetition and commoditization characterize the in...
Breaking Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-...r the "Company") (NYSE: SCR ), a leading pharmac...anufacturing, and marketing of branded,generic and...ted that its,subsidiary Jiangsu Yanshen Biological...s suspended production of all its products in orde...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewsw...cluding a late-breaking presentation on Tasigna...ic myeloid leukemia, demonstrate the strength of t... care of patients. ,, The new data, at the 51s...ing and Exposition, highlight the company,s curren...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 1Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 2Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2